NCT02711852View on ClinicalTrials.gov

A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

May 4, 2020

Study Completion Date

May 4, 2020

Conditions
Hematologic Malignancy
Interventions
DRUG

Duvelisib

Administered as oral capsules

Trial Locations (5)

34232

Sarasota

37203

Nashville

77030

UT MD Anderson Cancer Center, Houston

80218

Denver

05100

Azienda Ospedaliera Santa Maria di Terni/SC Oncoematologia, Terni

All Listed Sponsors
lead

SecuraBio

INDUSTRY

NCT02711852 - A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145) | Biotech Hunter | Biotech Hunter